Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

PROSTATE CANCER IN 2018

Immunotherapy for lethal prostate cancer

Nature Reviews Urology volume 16, pages 69–70 (2019)Cite this article

Subjects

Immunotherapy and tumour microenvironment modulation are potential new treatment approaches for metastatic prostate cancer, but patient selection might be key to delivering therapeutic benefit. In the past year, four studies have suggested that DNA mismatch repair alterations and CDK12 aberrations are biomarkers of response to immune checkpoint inhibitors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: T cell infiltration in mCRPC.

References

  1. Shen, X. & Zhao, B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362, k3529 (2018).

    Article  Google Scholar 

  2. Le, D. T. et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

    Article  CAS  Google Scholar 

  3. Beer, T. M. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40–47 (2017).

    Article  CAS  Google Scholar 

  4. De Bono, J. S. et al. KEYNOTE-199: pembrolizumab(pembro) for docetaxel- refractory metastatic castration- resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 36, 5007 (2018).

    Article  Google Scholar 

  5. Nava Rodrigues, D. et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J. Clin. Invest. 128, 4441–4453 (2018).

    Article  Google Scholar 

  6. Wu, Y. M. et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770–1782 (2018).

    Article  CAS  Google Scholar 

  7. Calcinotto, A. et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559, 363–369 (2018).

    Article  CAS  Google Scholar 

  8. Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728–732 (2017).

    Article  CAS  Google Scholar 

  9. Wang, J. J. et al. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat. Med. 22, 488–496 (2016).

    Article  CAS  Google Scholar 

  10. Sfanos, K. S. et al. The inflammatory microenvironment and microbiome in prostate cancer development. Nat. Rev. Urol. 15, 11–24 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Studies, The Institute of Cancer Research, London, UK

    Pasquale Rescigno & Johann S. de Bono

  2. Prostate Targeted Therapy Group, The Royal Marsden Hospital, London, UK

    Pasquale Rescigno & Johann S. de Bono

  3. Department of Clinical Medicine and Surgery, Department of Translational Medical Sciences, AOU Federico II, Naples, Italy

    Pasquale Rescigno

Authors
  1. Pasquale Rescigno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johann S. de Bono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johann S. de Bono.

Ethics declarations

Competing interests

J.S.d.B. has served as a consultant and advisory member for Astellas Pharma, AstraZeneca, Bayer, Genmab, Genentech, GlaxoSmithKline, Janssen, Medivation, Orion Pharma, Pfizer, and Sanofi. P.R. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rescigno, P., de Bono, J.S. Immunotherapy for lethal prostate cancer. Nat Rev Urol 16, 69–70 (2019). https://doi.org/10.1038/s41585-018-0121-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0121-y

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer